Researchers detected constitutive phosphorylation of spleen tyrosine kinase (SYK) in infant acute lymphoblastic leukemia PDX, the combination of SYK inhibitor and chemotherapy could significantly enhance therapeutic efficacy.163 Nonetheless, they also found RAS-mediated resistance to SYK inhibition, which indicates the complexity of the whole genome picture and emphasizes the importance of personalized detection and treatment. This evidence concerns the gene SYK and acute lymphoblastic leukemia.